AB
EGRX

Amalgamated Bank’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Amalgamated Bank’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-394
Closed -$2K – 3148
2024
Q1 		$2K Sell
394
-554
-58% -$3.04K ﹤0.01% 2908
2023
Q4 		$5K Sell
948
-117
-11% -$1.16K ﹤0.01% 2950
2023
Q3 		$17K Hold
1,065
– – ﹤0.01% 2742
2023
Q2 		$21K Sell
1,065
-3,492
-77% -$82.8K ﹤0.01% 2736
2023
Q1 		$129K Sell
4,557
-107
-2% -$3.18K ﹤0.01% 1951
2022
Q4 		$136K Sell
4,664
-495
-10% -$15.7K ﹤0.01% 2007
2022
Q3 		$136K Sell
5,159
-147
-3% -$5.39K ﹤0.01% 2005
2022
Q2 		$236K Buy
5,306
+10
+0.2% +$459 ﹤0.01% 1801
2022
Q1 		$262K Sell
5,296
-340
-6% -$16.3K ﹤0.01% 1825
2021
Q4 		$287K Sell
5,636
-264
-4% -$13.7K ﹤0.01% 1848
2021
Q3 		$329K Sell
5,900
-97
-2% -$4.77K ﹤0.01% 1805
2021
Q2 		$257K Buy
+5,997
New +$247K ﹤0.01% 1950

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Bank's EGRX Position: Q2 2024 in Review

Amalgamated Bank sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 394 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in EGRX in Q2 2021 and held it in 12 quarters. The position peaked at $329K in Q3 2021. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Amalgamated Bank reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Amalgamated Bank sold 394 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $2K.
  • Amalgamated Bank first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2021 and held it in 12 quarters.
  • Amalgamated Bank's Eagle Pharmaceuticals, Inc. position peaked at $329K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Amalgamated Bank's 13F filing for Q2 2024, filed 12 Aug 2024.